Event JSON
{
"id": "7b37f80e09443dae2e77259a1ac9f3617ba7c6b448e20c4260f2f50680c83b79",
"pubkey": "bd200f91f5f6f2d94b71e5c179a3291de2d6eb025724518b8f0f1356117e4d21",
"created_at": 1738263517,
"kind": 1,
"tags": [
[
"imeta",
"url https://amicale.net/system/media_attachments/files/113/918/837/536/643/887/original/835a149797c6b5d6.jpg",
"m image/jpeg"
],
[
"proxy",
"https://amicale.net/@reuters/113918837866147167",
"web"
],
[
"proxy",
"https://amicale.net/users/reuters/statuses/113918837866147167",
"activitypub"
],
[
"L",
"pink.momostr"
],
[
"l",
"pink.momostr.activitypub:https://amicale.net/users/reuters/statuses/113918837866147167",
"pink.momostr"
],
[
"-"
]
],
"content": "Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, https://clinicaltrials.gov/ entry shows https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisks-new-cagrisema-obesity-drug-trial-begin-feb-10-clinicaltrialsgov-2025-01-30/?taid=679bc07df78197000153773c\u0026utm_medium=Social\u0026utm_source=Mastodon\nhttps://amicale.net/system/media_attachments/files/113/918/837/536/643/887/original/835a149797c6b5d6.jpg\n",
"sig": "a335403a2907190d73cc254d77db3c4a0806ee0159da4f51440898f03e158b92a41e03470fb72738d8d62eeeac870d005d857088281bdc56e64660c4eaaf03e0"
}
